# Efficacy Study of SYN006 HFA MDI in Asthma Patients

> **NCT02162784** · PHASE2 · COMPLETED · sponsor: **Intech Biopharm Ltd.** · enrollment: 39 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Budesonide/Procaterol, 180/10mcg X1
- **DRUG:** Budesonide/procaterol 180/10 mcg X 2
- **DRUG:** Albuterol HFA MDI 100mcg X2

## Key facts

- **NCT ID:** NCT02162784
- **Lead sponsor:** Intech Biopharm Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2015-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02162784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02162784, "Efficacy Study of SYN006 HFA MDI in Asthma Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02162784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*